Androgen Receptor Splice Variants in Prostate Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for prostate cancer, particularly androgen refractory prostate cancer, are ineffective due to the continued expression of androgen receptor (AR) signaling pathways, which are not adequately inhibited by existing anti-androgen drugs, and there is a need for novel markers and therapeutic targets to address the progression and treatment of this stage of the disease.
Innovation Solution
Identification and characterization of novel androgen receptor splice variants (AR3, AR4, AR4b, AR5, and AR8) that lack the ligand binding domain but retain the N-terminal transactivation and DNA binding domains, which can serve as prognostic markers and therapeutic targets, using methodologies such as antisense technology, RNAi, and antibody technology to modulate their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional androgen ablation therapy is used to treat prostate cancer, then initial response is favorable due to apoptosis of androgen-sensitive tumor cells, but the therapy becomes ineffective in androgen refractory prostate cancer where AR signaling pathways continue to drive tumor growth
Solution Approach 1:
The patent segments the androgen receptor into different splice variants (AR3, AR4, AR4b, AR5, AR8) with distinct functional domains. By targeting specific variants that lack the ligand binding domain but retain transactivation and DNA binding domains, the therapy can selectively inhibit androgen-independent signaling pathways that persist after conventional androgen ablation, thereby extending the duration of therapy effectiveness.
Solution Approach 2:
The patent changes the target parameter from the full-length androgen receptor to specific splice variants with altered domain compositions. This parameter change allows differentiation between androgen-sensitive (full-length AR) and androgen-independent (splice variants) tumor cells, enabling extended therapy effectiveness by targeting the specific molecular parameters that drive androgen refractory disease.
2Reliability
If anti-androgen drugs are used to inhibit AR signaling, then androgen-sensitive prostate cancer responds well, but androgen refractory prostate cancer progresses due to continued AR expression and signaling
Solution Approach 1:
The patent applies local quality by targeting specific local regions (splice variants) of the androgen receptor that are differentially expressed in androgen refractory cancer. The splice variants AR3, AR4, AR4b, AR5, and AR8 have unique domain structures (lacking ligand binding domain) that are specifically present in hormone-refractory tumors, allowing localized therapeutic intervention without affecting normal androgen-sensitive pathways.
Solution Approach 2:
The patent creates a molecular copy distinction between the full-length androgen receptor and its splice variants. By detecting and targeting the specific splice variant copies (AR3, AR4, AR4b, AR5, AR8) that lack the ligand binding domain, the therapy achieves high specificity for androgen-independent disease, differentiating these pathological copies from the normal full-length receptor.
3Ease of operation
If current anti-androgen therapies are used, then treatment is simplified, but the complexity of AR signaling pathways and splice variants makes complete inhibition difficult
Solution Approach 1:
The patent segments the complex AR signaling pathway into distinct functional components represented by different splice variants. By identifying and targeting specific segments (AR3, AR4, AR4b, AR5, AR8) that are characteristic of androgen refractory disease, the therapy simplifies the operational complexity by focusing on specific actionable targets rather than attempting to inhibit all possible AR signaling pathways simultaneously.
Solution Approach 2:
The patent introduces splice variant-specific antibodies or therapeutic agents as intermediary molecules that mediate between the complex AR signaling network and the therapeutic intervention. These intermediaries selectively bind to and inhibit specific splice variants, simplifying the overall therapy by providing a targeted mechanism that bypasses the need to address all pathway complexity at once.
Data Source
AI summary
The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and methods which can be used to identify and treat prostate cancer based on these novel androgen receptor splice variants, as well as methods for screening agents which modulate the activity and/or expression of the androgen receptor splice variants. Vectors, host cells and recombinant methods for producing the same and transgenic animals are also provided.